Changes, Challenges and Opportunities in Cancer Care During the COVID-19 Era and Beyond: Building on Lessons Learned From the Pandemic | Kidney Cancer Journal
KCJ Roundtable Monograph Open Access
Changes, Challenges and Opportunities in Cancer Care During the COVID-19 Era and Beyond: Building…
The third quarter of 2026 was defined less by new readouts than by regulatory follow-through. Data from ASCO GU and the ASCO Annual Meeting turned into FDA approvals in muscle-invasive bladder cancer and metastatic hormone-sensitive prostate cancer, and biomarker-selected strategies moved firmly…
Journal Club selections are curated by the Kidney Cancer Journal editorial team based on clinical significance, study design rigor, and potential impact on practice. Full-text access available via PubMed and respective journal platforms.
Belzutifan plus lenvatinib versus cabozantinib in patients with previously…
█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…
Moshe C. Ornstein1,#, Xiayan Ye2,3, Sumita Dutta2,3, Venkateshwari Varadharajan2,3, Wei Wei4, Marcelo Lamenza1, Monaben Patel5, C. Marcela Diaz-Montero5, J. Mark Brown2,3,6,#, and Abhishek A. Chakraborty5,6,#Ϯ
ABSTRACT BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting…
Perspectives synthesized from ASCO 2026 presenter and discussant sessions and post-meeting expert commentary. Prepared for educational purposes by the Kidney Cancer Journal editorial team.
Toni K. Choueiri, MD, FASCO. Dana-Farber Cancer Institute, Boston, MA. Presenter — LITESPARK-022 and KEYNOTE-564 ctDNA Analysis…
doi.org/10.52733/ASCO26Summary
Thomas E. Hutson, DO, PharmD, FACP
Editor-in-Chief, Kidney Cancer Journal
A Summary Report for the Global Oncology Community
Chicago, Illinois | May 29 – June 2, 2026 | Kidney Cancer Journal, Volume 24…
Selected by the Editor-in-Chief | Kidney Cancer Journal, Volume 24(2)
Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary.
Abstract 1 — LBA418
LITESPARK-022: Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Clear…
May 29–June 2, 2026 | Chicago, IL
Senthil Pazhanisamy, BPharma, MS, PhD.
Overview
The 2026 ASCO Annual Meeting arrives at a critical inflection point for renal cell carcinoma (RCC). The February ASCO GU Symposium in San Francisco delivered a rapid sequence of…
Nitinkumar Moradiya
University Of Sunderland, Harbour Exchange Square, E14 9GE, London, United Kingdom.
ABSTRACT
Background: Kidney cancer is an emerging public health concern in India, with rising incidence rates and a significant economic burden. While global research has identified common risk…
